🟢 Eupraxia Pharmaceuticals is trading 8.63% up in pre-market after positive RESOLVE trial findings

Eupraxia Pharmaceuticals is trading 8.63% up now at $7.30 after positive RESOLVE trial findings for EP-104GI in eosinophilic esophagitis.

• Painful and difficult swallowing showed sustained reductions; moderate or severe odynophagia fell from 62% at baseline to 25% after 52 weeks.
• Favorable tolerability included no treatment-emergent or procedure-related serious adverse events.
• The move follows a 0.75% gain on August 14 and the August 13 update; broader markets were modestly mixed-to-positive, but clinical news is the clearest catalyst.